ArticleOncology letters2024

Blood MALT1 serves as a potential biomarker reflecting the response and survival of immune‑checkpoint‑inhibitor therapy in advanced hepatocellular carcinoma.

Weiping Ma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.